Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Next Previous
X
Search
Trial Profile

A Phase 1b/2 Randomized Study of AVB-S6-500 Plus Nab-paclitaxel and Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Batiraxcept (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aravive

    • Most Recent Events

    • 26 Oct 2023 Status changed from recruiting to discontinued.
    • 28 Jul 2023 According to Aravive media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2023
    • 06 Jun 2023 Results (n=21, as of data cut off date of January 17, 2023) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top